News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
493,037 Results
Type
Article (47563)
Company Profile (33)
Press Release (445441)
Multimedia
Podcasts (19)
Webinars (10)
Section
Business (139340)
Career Advice (1173)
Deals (26345)
Drug Delivery (82)
Drug Development (63649)
Employer Resources (92)
FDA (12842)
Job Trends (11299)
News (247160)
Policy (25564)
Tag
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Premier (1)
Academia (2718)
Academic (1)
Accelerated approval (5)
Adcomms (14)
Allergies (65)
Alliances (34007)
ALS (68)
Alzheimer's disease (1172)
Antibody-drug conjugate (ADC) (97)
Approvals (12871)
Artificial intelligence (164)
Autoimmune disease (14)
Automation (8)
Bankruptcy (275)
Best Places to Work (9070)
BIOSECURE Act (16)
Biosimilars (82)
Biotechnology (30)
Bladder cancer (53)
Brain cancer (26)
Breast cancer (223)
Cancer (1725)
Cardiovascular disease (135)
Career advice (958)
Career pathing (15)
CAR-T (125)
Cell therapy (320)
Cervical cancer (19)
Clinical research (51800)
Collaboration (605)
Compensation (157)
Complete response letters (24)
COVID-19 (2351)
CRISPR (29)
C-suite (188)
Cystic fibrosis (74)
Data (1779)
Decentralized trials (1)
Denatured (11)
Depression (32)
Diabetes (207)
Diagnostics (5008)
Digital health (9)
Diversity (7)
Diversity, equity & inclusion (29)
Drug discovery (79)
Drug pricing (76)
Drug shortages (16)
Duchenne muscular dystrophy (77)
Earnings (52745)
Editorial (20)
Employer branding (11)
Employer resources (81)
Events (59517)
Executive appointments (602)
FDA (13835)
Featured Employer (13)
Friedreich's ataxia (1)
Frontotemporal dementia (6)
Funding (516)
Gene editing (73)
Generative AI (14)
Gene therapy (206)
GLP-1 (514)
Government (3485)
Grass and pollen (3)
Guidances (45)
Healthcare (14742)
Huntington's disease (15)
IgA nephropathy (20)
Immunology and inflammation (80)
Indications (25)
Infectious disease (2464)
Inflammatory bowel disease (111)
Inflation Reduction Act (8)
Influenza (43)
Intellectual property (82)
Interviews (189)
IPO (13261)
IRA (27)
Job creations (2537)
Job search strategy (839)
Kidney cancer (9)
Labor market (21)
Layoffs (356)
Leadership (5)
Legal (6375)
Liver cancer (55)
Lung cancer (262)
Lymphoma (118)
Machine learning (3)
Management (25)
Manufacturing (234)
MASH (55)
Medical device (10016)
Medtech (10018)
Mergers & acquisitions (13551)
Metabolic disorders (505)
Multiple sclerosis (68)
NASH (14)
Neurodegenerative disease (70)
Neuropsychiatric disorders (17)
Neuroscience (1587)
NextGen: Class of 2025 (4895)
Non-profit (3549)
Northern California (1864)
Now hiring (17)
Obesity (246)
Opinion (89)
Ovarian cancer (71)
Pain (71)
Pancreatic cancer (70)
Parkinson's disease (118)
Partnered (19)
Patents (192)
Patient recruitment (83)
Peanut (40)
People (44917)
Pharmaceutical (13)
Pharmacy benefit managers (17)
Phase I (15495)
Phase II (22858)
Phase III (17750)
Pipeline (988)
Policy (92)
Postmarket research (1931)
Preclinical (6558)
Press Release (42)
Prostate cancer (83)
Psychedelics (25)
Radiopharmaceuticals (202)
Rare diseases (273)
Real estate (4473)
Recruiting (36)
Regulatory (17408)
Reports (27)
Research institute (2001)
Resumes & cover letters (195)
Rett syndrome (4)
RNA editing (2)
RSV (35)
Schizophrenia (56)
Series A (75)
Series B (47)
Service/supplier (5)
Sickle cell disease (41)
Southern California (1650)
Special edition (10)
Spinal muscular atrophy (118)
Sponsored (20)
Startups (2372)
State (2)
Stomach cancer (8)
Supply chain (44)
Tariffs (7)
The Weekly (8)
United States (16466)
Vaccines (588)
Venture capitalists (19)
Weight loss (158)
Women's health (23)
Worklife (4)
Date
Today (7)
Last 7 days (346)
Last 30 days (1804)
Last 365 days (25242)
2025 (6994)
2024 (27198)
2023 (30936)
2022 (38204)
2021 (44302)
2020 (43061)
2019 (34678)
2018 (26727)
2017 (24700)
2016 (22748)
2015 (27251)
2014 (19907)
2013 (16779)
2012 (17888)
2011 (18530)
2010 (16771)
Location
Africa (528)
Alabama (46)
Alaska (5)
Arizona (120)
Arkansas (11)
Asia (29803)
Australia (5127)
California (4251)
Canada (1595)
China (377)
Colorado (213)
Connecticut (214)
Delaware (92)
Europe (63282)
Florida (724)
Georgia (152)
Idaho (40)
Illinois (400)
India (16)
Indiana (236)
Iowa (7)
Japan (122)
Kansas (86)
Kentucky (17)
Louisiana (7)
Maine (50)
Maryland (597)
Massachusetts (2860)
Michigan (163)
Minnesota (227)
Mississippi (2)
Missouri (59)
Montana (26)
Nebraska (15)
Nevada (57)
New Hampshire (55)
New Jersey (1379)
New Mexico (16)
New York (1354)
North Carolina (725)
North Dakota (3)
Northern California (1864)
Ohio (136)
Oklahoma (13)
Oregon (19)
Pennsylvania (1012)
Puerto Rico (10)
Rhode Island (21)
South America (791)
South Carolina (16)
South Dakota (1)
Southern California (1650)
Tennessee (88)
Texas (704)
Utah (130)
Virginia (115)
Washington D.C. (45)
Washington State (441)
West Virginia (3)
Wisconsin (29)
493,037 Results for "mississippi state university".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing
Halberd Corporation’s Traumatic Brain Injury mitigating nasal spray testing protocols at Mississippi State University were approved by the Institutional Animal Care and Use Committee.
February 8, 2024
·
3 min read
Pharm Country
Halberd Corporation Plans to Extend Research Partnership with Mississippi State University
Halberd Corporation is in talks with Mississippi State University to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects.
November 15, 2023
·
3 min read
Pharm Country
Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses
Halberd Corporation’s Traumatic Brain Injury mitigation research on Halberd’s patent-pending nasal spray continues at Mississippi State University.
August 14, 2023
·
4 min read
Business
Halberd’s Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)
Halberd Corporation’s (OTC PINK:HALB) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results.
October 4, 2023
·
4 min read
Pharm Country
Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects.
August 22, 2023
·
3 min read
Policy
Astounding Early Test Results of Halberd’s Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)
Halberd Corporation’s research at Mississippi State University has shown significant reduction in two key markers of traumatic brain injury in early testing of Halberd’s patent-pending nasal spray to mitigate the effects of TBI.
September 6, 2023
·
4 min read
Drug Development
Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete
Halberd Corporation announced Mississippi State University has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd’s groundbreaking patent-pending nasal spray.
May 23, 2023
·
4 min read
Drug Development
Halberd Begins Preclinical Testing at Mississippi State University (MSU)
Halberd Corporation (OTC PINK:HALB) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI).
April 11, 2023
·
3 min read
Press Releases
The Caris Precision Oncology Alliance Welcomes The University of Mississippi Medical Center
July 25, 2024
·
4 min read
Drug Development
Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma
Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU.
March 30, 2023
·
4 min read
1 of 49,304
Next
